MedTrace Logo

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

NCT01069692 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2020-12-19

No results posted yet for this study

Summary

This study will compare placebo to 4 different doses of SBR759 to assess the phosphate lowering efficacy in dialysis patients.

Conditions

Interventions

DRUG

SBR759A

SBR759A 6g daily

DRUG

SBR759A

Placebo Comparator 0g daily

DRUG

SBR759A

SBR759A 3g daily

DRUG

SBR759A

9g daily

DRUG

SBR759A

12g daily

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-10-31

Countries

  • Belgium
  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069692 on ClinicalTrials.gov